Using a neurofilament light chain serum test to determine multiple sclerosis treatment effect


  • Neurofilament light chain (NfL) has the potential to be a helpful biomarker to measure disease severity and treatment response in people with multiple sclerosis (MS).

Why this matters

  • People with MS typically receive a yearly magnetic resonance imaging (MRI) scan, however this is an expensive and semiqualitative way to monitor disease activity and does not monitor treatment response well.
  • Using a blood or cerebrospinal fluid (CSF) test for NfL would be a cheaper and easier way to clinically monitor disease state and treatment response.